Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intranasal recombinant adenovirus-vectored vaccine
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The **intranasal recombinant adenovirus-vectored vaccine** is an investigational therapeutic vaccine developed by West China Hospital of Sichuan University. It utilizes a recombinant adenovirus vector to deliver specific antigens, primarily targeting **HPV16-positive** malignancies. Administered via the intranasal route, the vaccine is designed to stimulate mucosal-associated lymphoid tissue (MALT) and induce both mucosal and systemic T-cell immune responses against viral oncoproteins (typically E6 and E7). This approach aims to overcome the immunosuppressive tumor microenvironment in diseases such as advanced **oropharyngeal squamous cell carcinoma**. It is currently being evaluated in Phase I clinical trials as a monotherapy and in combination with the PD-1 checkpoint inhibitor tislelizumab to assess safety, immunogenicity, and preliminary antitumor activity.
- Other names
- intranasal recombinant adenovirus-vectored HPV16 vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E6 oncoprotein
Beyond the preview
Go deeper on intranasal recombinant adenovirus-vectored vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intranasal recombinant adenovirus-vectored vaccine.